Accure Acne, Inc. has launched a private placement offering on the M-Vest platform to raise up to $20 Million.

Building on the research of R. Rox Anderson, MD, Accure Co-Founder and Chief Scientific & Medical Officer, Accure has developed the Accure Laser System, an energy-based device that targets sebaceous glands. The company believes the technology utilizes a novel, proprietary treatment method that has been demonstrated on human tissue to damage sebaceous glands through selective photothermolysis, while sparing the surrounding epidermis from damage.

In March 2020, Accure's exclusive manufacturing partner for the Accure Laser System, Quanta System S.p.A, received clearance for CE Mark certification. Accure believes this is the only 1726nm laser with CE  Mark clearance for the treatment of moderate inflammatory acne.